849 related articles for article (PubMed ID: 32293710)
1. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
Brufsky A
J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
3. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
4. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
5. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
6. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Gupta SP
Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
[TBL] [Abstract][Full Text] [Related]
7. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
8. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: Immunology and treatment options.
Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer.
Mihalopoulos M; Dogra N; Mohamed N; Badani K; Kyprianou N
Eur Urol Focus; 2020 Sep; 6(5):1086-1096. PubMed ID: 32540268
[TBL] [Abstract][Full Text] [Related]
13. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H; Pillat MM
Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653
[TBL] [Abstract][Full Text] [Related]
14. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.
Fu J; Zhou B; Zhang L; Balaji KS; Wei C; Liu X; Chen H; Peng J; Fu J
Mol Biol Rep; 2020 Jun; 47(6):4383-4392. PubMed ID: 32410141
[TBL] [Abstract][Full Text] [Related]
15. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
[TBL] [Abstract][Full Text] [Related]
16. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Saxena A
J Biosci; 2020; 45(1):. PubMed ID: 32661214
[TBL] [Abstract][Full Text] [Related]
17. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
18. Cancer therapy and treatments during COVID-19 era.
Akula SM; Abrams SL; Steelman LS; Candido S; Libra M; Lerpiriyapong K; Cocco L; Ramazzotti G; Ratti S; Follo MY; Martelli AM; Blalock WL; Piazzi M; Montalto G; Cervello M; Notarbartolo M; Basecke J; McCubrey JA
Adv Biol Regul; 2020 Aug; 77():100739. PubMed ID: 32773105
[TBL] [Abstract][Full Text] [Related]
19. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]